Price Disclosure Reductions for 2016 April Cycle
Page last updated: 16 December 2016
This summary of 1 April 2016 price disclosure reductions for the 2016 April Cycle only includes medicines taking a price disclosure reduction. The price disclosure legal determination mentioned below includes brands where there will not be a price disclosure reduction (see Schedule 2 of the determination).
The price disclosure outcomes for this cycle were calculated in accordance with the National Health Act 1953 (the Act) and National Health (Pharmaceutical Benefits) Regulations 1960 (the Regulations) in place as at September 2015.
The outcomes below show percentage (%) price differences and ex-manufacturer level prices. They do not include fees and mark-ups.
2015 Price Disclosure Changes
The 2016 April Cycle is the first price disclosure cycle that incorporates the ‘Flow-on Reductions for F2 Combination Items’ and the ‘No Reduction Items – Low Volume / Low Discount’ measures announced under the 2015 Access and Sustainability package of changes to the Pharmaceutical Benefits Scheme (PBS).
Flow-on Reductions for F2 Combination Items
Responsible persons with a brand of an F2 combination item should understand that:
- if your brand of F2 combination item received a direct price disclosure reduction, this reduction may not take effect on 1 April 2016 if the price of a component ingredient will be reduced on 1 April 2016, and flowing this price on to the combination item will result in a lower price than that of the direct reduction; or
- if your brand of F2 combination item did not receive a direct price disclosure reduction, it may still receive a price reduction as a result of the flow-on of the price of a component ingredient that is taking a price disclosure reduction.
Calculations are currently being completed for flow-on price disclosure reductions to F2 combination items. Outcomes will be communicated to responsible persons with brands of affected drugs. Letters will set out the new prices for F2 combination items and seek PB11a forms. F2 combination item pricing will require attention by affected companies during January 2016. This aligns with the usual timeline for combination flow-on pricing for April reduction days.
No Reduction Items – Low Volume / Low Discount
This measure allows for no price disclosure reduction for certain pharmaceutical items with low volume and low discounting, even where other items with the same drug and manner of administration (MoA) will take a reduction on 1 April 2016.
The 2016 April Cycle is the first price disclosure cycle that incorporates the ‘Low Volume / Low Discount’ measure.
Further information regarding these changes can be found on the 2015 Price Disclosure Changes - Fact Sheet.
Legal Determination & Next Steps
The weighted average disclosed prices for each brand, including brands with no reduction, are in the legal determination on the ComLaw website. Price disclosure reductions will apply to brands listed in Schedule 1 of the legal determination. Those brands in Schedule 2 of the determination will not take a price disclosure reduction because the percentage difference between their October 2015 PBS approved ex-manufacturer price and the weighted average disclosed price for the 2016 April Cycle was below 10%. Any new brands of an existing pharmaceutical item with a determination in Schedule 1 that listed after 30 September 2015 will also take the reduction on 1 April 2016 under section 99ADHA of the Act.
An agreed process for responsible persons to raise any questions or concerns arising from an outcome mentioned above is set out in the Price Disclosure Dispute Resolution Administrative Process. The date for lodgement of disputes is 5 pm AEDT on Wednesday, 23 December 2015.
Indicative prices for 1 April 2016 (including price to pharmacy, Dispensed Price for Maximum Quantity and price premiums) will be published by late January 2016. Subscribe to PBS News to receive notice when they become available.
Final prices for 1 April 2016 (including all price to pharmacy, Dispensed Price for Maximum Quantity/Amount and price premiums) will be available from early March 2016.
| Legal Instrument Drug (drugs marked with an * have a pharmaceutical item/s that met the ‘Low Volume Low Discount criteria’ therefore those items will not take a reduction) |
Legal Instrument MoA | Legal Instrument Form | Average AEMP ($) |
WAPD (%) across a drug/MoA |
WADP - potential April '16 PBS Price (AEMP) ($) per pharmaceutical item |
October '15 AEMP ($) |
Percentage difference between October '15 and April '16 PBS prices (AEMP) (%) per pharmaceutical item |
|---|---|---|---|---|---|---|---|
| [Average AEMP minus WAPD = WADP] | [Difference between October AEMP & WADP = % Difference] |
||||||
|
alendronic acid with colecalciferol and calcium |
oral |
pack containing 4 tablets containing alendronic acid 70 mg (as alendronate sodium) with 140 micrograms colecalciferol and 48 tablets calcium 500 mg (as carbonate) |
31.85 |
13.67% |
27.50 |
31.85 |
13.66% |
|
amisulpride |
oral |
tablet 100 mg |
10.07 |
14.96% |
8.56 |
10.07 |
15.00% |
|
amisulpride |
oral |
tablet 200 mg |
43.35 |
14.96% |
36.86 |
43.35 |
14.97% |
|
amisulpride |
oral |
tablet 400 mg |
78.61 |
14.96% |
66.85 |
78.61 |
14.96% |
|
amlodipine |
oral |
tablet 10 mg (as besylate) |
2.12 |
16.96% |
1.76 |
2.12 |
16.98% |
|
amlodipine |
oral |
tablet 5 mg (as besylate) |
1.21 |
16.96% |
1.00 |
1.21 |
17.36% |
|
anastrozole |
oral |
tablet 1 mg |
66.65 |
26.24% |
49.16 |
55.73 |
11.79% |
|
atorvastatin |
oral |
tablet 10 mg (as calcium) |
3.76 |
37.09% |
2.37 |
2.78 |
14.75% |
|
atorvastatin |
oral |
tablet 20 mg (as calcium) |
5.55 |
37.09% |
3.49 |
4.10 |
14.88% |
|
atorvastatin |
oral |
tablet 40 mg (as calcium) |
7.82 |
37.09% |
4.92 |
5.77 |
14.73% |
|
atorvastatin |
oral |
tablet 80 mg (as calcium) |
11.18 |
37.09% |
7.03 |
8.25 |
14.79% |
|
azathioprine |
oral |
tablet 25 mg |
15.74 |
10.02% |
14.16 |
15.74 |
10.04% |
|
azathioprine |
oral |
tablet 50 mg |
26.79 |
10.02% |
24.11 |
26.79 |
10.00% |
|
azithromycin |
oral |
tablet 500 mg (as dihydrate) |
5.25 |
13.51% |
4.54 |
5.25 |
13.52% |
|
azithromycin |
oral |
tablet 600 mg (as dihydrate) |
64.03 |
13.51% |
55.38 |
64.03 |
13.51% |
|
bicalutamide |
oral |
tablet 50 mg |
81.83 |
14.07% |
70.32 |
81.83 |
14.07% |
|
bisoprolol |
oral |
tablet containing bisoprolol fumarate 10 mg |
21.89 |
24.04% |
16.63 |
18.68 |
10.97% |
|
bisoprolol |
oral |
tablet containing bisoprolol fumarate 2.5 mg |
14.01 |
24.04% |
10.64 |
11.96 |
11.04% |
|
bisoprolol |
oral |
tablet containing bisoprolol fumarate 5 mg |
17.51 |
24.04% |
13.30 |
14.94 |
10.98% |
|
candesartan |
oral |
tablet containing candesartan cilexetil 16 mg |
9.88 |
33.43% |
6.58 |
7.85 |
16.18% |
|
candesartan |
oral |
tablet containing candesartan cilexetil 32 mg |
11.94 |
33.43% |
7.95 |
9.49 |
16.23% |
|
candesartan |
oral |
tablet containing candesartan cilexetil 4 mg |
1.11 |
33.43% |
0.74 |
0.88 |
15.91% |
|
candesartan |
oral |
tablet containing candesartan cilexetil 8 mg |
3.30 |
33.43% |
2.20 |
2.62 |
16.03% |
|
capecitabine |
oral |
tablet 150 mg |
83.46 |
63.22% |
30.70 |
40.04 |
23.33% |
|
capecitabine |
oral |
tablet 500 mg |
517.39 |
63.22% |
190.30 |
248.19 |
23.32% |
|
carvedilol |
oral |
tablet 12.5 mg |
15.18 |
13.60% |
13.12 |
15.18 |
13.57% |
|
carvedilol |
oral |
tablet 25 mg |
18.98 |
13.60% |
16.40 |
18.98 |
13.59% |
|
carvedilol |
oral |
tablet 3.125 mg |
2.57 |
13.60% |
2.22 |
2.57 |
13.62% |
|
carvedilol |
oral |
tablet 6.25 mg |
12.14 |
13.60% |
10.49 |
12.14 |
13.59% |
|
celecoxib |
oral |
capsule 100 mg |
17.59 |
38.62% |
10.80 |
17.59 |
38.60% |
|
celecoxib |
oral |
capsule 200 mg |
17.59 |
38.62% |
10.80 |
17.59 |
38.60% |
|
clindamycin |
oral |
capsule 150 mg (as hydrochloride) |
9.06 |
13.18% |
7.87 |
9.06 |
13.13% |
|
clopidogrel |
oral |
tablet 75 mg |
7.23 |
23.35% |
5.54 |
7.23 |
23.37% |
|
clopidogrel |
oral |
tablet 75 mg (as besilate) |
7.23 |
23.35% |
5.54 |
7.23 |
23.37% |
|
clopidogrel |
oral |
tablet 75 mg (as hydrogen sulfate) |
7.23 |
23.35% |
5.54 |
7.23 |
23.37% |
|
clopidogrel with aspirin |
oral |
tablet 75 mg (as hydrogen sulfate)-100 mg |
27.33 |
23.93% |
20.79 |
27.33 |
23.93% |
|
desvenlafaxine |
oral |
tablet (extended release) 100 mg (as succinate) |
29.29 |
22.66% |
22.65 |
29.29 |
22.67% |
|
desvenlafaxine |
oral |
tablet (extended release) 50 mg (as succinate) |
23.85 |
22.66% |
18.45 |
23.85 |
22.64% |
|
desvenlafaxine |
oral |
tablet (modified release) 100 mg |
29.29 |
22.66% |
22.65 |
29.29 |
22.67% |
|
desvenlafaxine |
oral |
tablet (modified release) 100 mg (as benzoate) |
29.29 |
22.66% |
22.65 |
29.29 |
22.67% |
|
desvenlafaxine |
oral |
tablet (modified release) 50 mg |
23.85 |
22.66% |
18.45 |
23.85 |
22.64% |
|
desvenlafaxine |
oral |
tablet (modified release) 50 mg (as benzoate) |
23.85 |
22.66% |
18.45 |
23.85 |
22.64% |
|
doxorubicin |
injection/intravesical |
solution for i.v. injection or intravesical administration containing doxorubicin hydrochloride 10 mg in 5 ml single dose vial |
2.20 |
20.87% |
1.74 |
2.20 |
20.91% |
|
doxorubicin |
injection/intravesical |
solution for i.v. injection or intravesical administration containing doxorubicin hydrochloride 100 mg in 50 ml single dose vial |
18.59 |
20.87% |
14.71 |
18.59 |
20.87% |
|
doxorubicin |
injection/intravesical |
solution for i.v. injection or intravesical administration containing doxorubicin hydrochloride 200 mg in 100 ml single dose vial |
37.17 |
20.87% |
29.41 |
37.17 |
20.88% |
|
doxorubicin |
injection/intravesical |
solution for i.v. injection or intravesical administration containing doxorubicin hydrochloride 50 mg in 25 ml single dose vial |
9.30 |
20.87% |
7.36 |
9.30 |
20.86% |
|
duloxetine |
oral |
capsule 30 mg (as hydrochloride) |
9.66 |
37.10% |
6.08 |
7.47 |
18.61% |
|
duloxetine |
oral |
capsule 60 mg (as hydrochloride) |
13.79 |
37.10% |
8.67 |
10.67 |
18.74% |
|
escitalopram |
oral |
tablet 10 mg (as oxalate) |
3.40 |
19.72% |
2.73 |
3.40 |
19.71% |
|
escitalopram |
oral |
tablet 20 mg (as oxalate) |
3.43 |
19.72% |
2.75 |
3.43 |
19.83% |
|
esomeprazole |
oral |
capsule (enteric) 20 mg (as magnesium) |
15.05 |
16.40% |
12.58 |
15.05 |
16.41% |
|
esomeprazole |
oral |
capsule (enteric) 40 mg (as magnesium) |
25.52 |
16.40% |
21.33 |
25.52 |
16.42% |
|
esomeprazole |
oral |
tablet (enteric coated) 20 mg (as magnesium trihydrate) |
15.05 |
16.40% |
12.58 |
15.05 |
16.41% |
|
esomeprazole |
oral |
tablet (enteric coated) 40 mg (as magnesium trihydrate) |
25.52 |
16.40% |
21.33 |
25.52 |
16.42% |
|
exemestane |
oral |
tablet 25 mg |
84.64 |
15.32% |
71.67 |
84.64 |
15.32% |
|
famciclovir |
oral |
tablet 125 mg |
42.50 |
26.18% |
31.37 |
36.22 |
13.39% |
|
famciclovir |
oral |
tablet 250 mg |
42.50 |
26.18% |
31.37 |
36.22 |
13.39% |
|
famciclovir |
oral |
tablet 500 mg |
63.75 |
26.18% |
47.06 |
54.33 |
13.38% |
|
fentanyl |
transdermal |
transdermal patch 1.28 mg |
12.73 |
16.08% |
10.68 |
12.73 |
16.10% |
|
fentanyl |
transdermal |
transdermal patch 10.20 mg |
50.59 |
16.08% |
42.46 |
50.59 |
16.07% |
|
fentanyl |
transdermal |
transdermal patch 12.375 mg |
40.77 |
16.08% |
34.21 |
40.77 |
16.09% |
|
fentanyl |
transdermal |
transdermal patch 12.6 mg |
40.77 |
16.08% |
34.21 |
40.77 |
16.09% |
|
fentanyl |
transdermal |
transdermal patch 16.5 mg |
50.59 |
16.08% |
42.46 |
50.59 |
16.07% |
|
fentanyl |
transdermal |
transdermal patch 16.8 mg |
50.59 |
16.08% |
42.46 |
50.59 |
16.07% |
|
fentanyl |
transdermal |
transdermal patch 2.063 mg |
12.73 |
16.08% |
10.68 |
12.73 |
16.10% |
|
fentanyl |
transdermal |
transdermal patch 2.1 mg |
12.73 |
16.08% |
10.68 |
12.73 |
16.10% |
|
fentanyl |
transdermal |
transdermal patch 2.55 mg |
16.19 |
16.08% |
13.59 |
16.19 |
16.06% |
|
fentanyl |
transdermal |
transdermal patch 4.125 mg |
16.19 |
16.08% |
13.59 |
16.19 |
16.06% |
|
fentanyl |
transdermal |
transdermal patch 4.2 mg |
16.19 |
16.08% |
13.59 |
16.19 |
16.06% |
|
fentanyl |
transdermal |
transdermal patch 5.10 mg |
29.75 |
16.08% |
24.97 |
29.75 |
16.07% |
|
fentanyl |
transdermal |
transdermal patch 7.65 mg |
40.77 |
16.08% |
34.21 |
40.77 |
16.09% |
|
fentanyl |
transdermal |
transdermal patch 8.25 mg |
29.75 |
16.08% |
24.97 |
29.75 |
16.07% |
|
fentanyl |
transdermal |
transdermal patch 8.4 mg |
29.75 |
16.08% |
24.97 |
29.75 |
16.07% |
|
fluoxetine |
oral |
capsule 20 mg (as hydrochloride) |
4.52 |
12.02% |
3.98 |
4.52 |
11.95% |
|
fluoxetine |
oral |
tablet, dispersible, 20 mg (as hydrochloride) |
4.52 |
12.02% |
3.98 |
4.52 |
11.95% |
|
folinic acid |
injection |
injection containing calcium folinate equivalent to 1000 mg folinic acid in 100 ml |
40.47 |
11.09% |
35.98 |
40.47 |
11.09% |
|
folinic acid |
injection |
injection containing calcium folinate equivalent to 300 mg folinic acid in 30 ml |
11.84 |
11.09% |
10.53 |
11.84 |
11.06% |
|
folinic acid |
injection |
injection containing calcium folinate equivalent to 50 mg folinic acid in 5 ml |
4.38 |
11.09% |
3.89 |
4.38 |
11.19% |
|
gabapentin |
oral |
capsule 100 mg |
5.00 |
13.90% |
4.31 |
5.00 |
13.80% |
|
gabapentin |
oral |
capsule 300 mg |
16.71 |
13.90% |
14.39 |
16.71 |
13.88% |
|
gabapentin |
oral |
capsule 400 mg |
22.79 |
13.90% |
19.62 |
22.79 |
13.91% |
|
gabapentin |
oral |
tablet 600 mg |
36.18 |
13.90% |
31.15 |
36.18 |
13.90% |
|
gabapentin |
oral |
tablet 800 mg |
48.23 |
13.90% |
41.53 |
48.23 |
13.89% |
|
irbesartan |
oral |
tablet 150 mg |
4.14 |
32.47% |
2.80 |
3.25 |
13.85% |
|
irbesartan |
oral |
tablet 300 mg |
8.27 |
32.47% |
5.58 |
6.50 |
14.15% |
|
irbesartan |
oral |
tablet 75 mg |
2.90 |
32.47% |
1.96 |
2.28 |
14.04% |
|
iron polymaltose complex |
injection |
injection 100 mg (iron) in 2 ml |
20.31 |
42.28% |
11.72 |
16.64 |
29.57% |
|
labetalol |
oral |
tablet containing labetalol hydrochloride 100 mg |
7.98 |
2.32% |
7.79 |
9.61 |
18.94% |
|
labetalol |
oral |
tablet containing labetalol hydrochloride 200 mg |
12.61 |
2.32% |
12.32 |
14.25 |
13.54% |
|
lamivudine* |
oral |
tablet 100 mg |
81.22 |
21.52% |
63.74 |
81.22 |
21.52% |
|
lamivudine* |
oral |
tablet 150 mg |
153.34 |
21.52% |
120.34 |
153.34 |
21.52% |
|
lamivudine* |
oral |
tablet 300 mg |
153.34 |
21.52% |
120.34 |
153.34 |
21.52% |
|
lamotrigine* |
oral |
tablet 100 mg |
22.28 |
20.49% |
17.71 |
22.28 |
20.51% |
|
lamotrigine* |
oral |
tablet 200 mg |
37.44 |
20.49% |
29.77 |
37.44 |
20.49% |
|
lamotrigine* |
oral |
tablet 25 mg |
8.02 |
20.49% |
6.38 |
8.02 |
20.45% |
|
lamotrigine* |
oral |
tablet 50 mg |
13.38 |
20.49% |
10.64 |
13.38 |
20.48% |
|
lansoprazole |
oral |
capsule 15 mg |
5.81 |
15.28% |
4.92 |
5.81 |
15.32% |
|
lansoprazole |
oral |
capsule 30 mg |
9.70 |
15.28% |
8.22 |
9.70 |
15.26% |
|
lansoprazole |
oral |
tablet 15 mg (orally disintegrating) |
5.40 |
15.28% |
4.57 |
5.40 |
15.37% |
|
lansoprazole |
oral |
tablet 30 mg (orally disintegrating) |
9.70 |
15.28% |
8.22 |
9.70 |
15.26% |
|
latanoprost |
application to the eye |
eye drops 50 micrograms per ml, 2.5 ml |
13.99 |
17.33% |
11.57 |
13.99 |
17.30% |
|
leflunomide |
oral |
tablet 10 mg |
35.04 |
13.29% |
30.38 |
35.04 |
13.30% |
|
leflunomide |
oral |
tablet 20 mg |
53.34 |
13.29% |
46.25 |
53.34 |
13.29% |
|
letrozole |
oral |
tablet 2.5 mg |
62.29 |
31.94% |
42.39 |
47.88 |
11.47% |
|
levetiracetam* |
oral |
tablet 1 g |
58.57 |
17.33% |
48.42 |
58.57 |
17.33% |
|
levetiracetam* |
oral |
tablet 250 mg |
21.09 |
17.33% |
17.44 |
21.09 |
17.31% |
|
levetiracetam* |
oral |
tablet 500 mg |
35.15 |
17.33% |
29.06 |
35.15 |
17.33% |
|
lisinopril |
oral |
tablet 10 mg |
3.92 |
10.73% |
3.50 |
3.92 |
10.71% |
|
lisinopril |
oral |
tablet 20 mg |
4.94 |
10.73% |
4.41 |
4.94 |
10.73% |
|
lisinopril |
oral |
tablet 5 mg |
2.62 |
10.73% |
2.34 |
2.62 |
10.69% |
|
meloxicam |
oral |
capsule 15 mg |
5.33 |
11.57% |
4.71 |
5.33 |
11.63% |
|
meloxicam |
oral |
capsule 7.5 mg |
3.65 |
11.57% |
3.23 |
3.65 |
11.51% |
|
meloxicam |
oral |
tablet 15 mg |
5.33 |
11.57% |
4.71 |
5.33 |
11.63% |
|
meloxicam |
oral |
tablet 7.5 mg |
3.65 |
11.57% |
3.23 |
3.65 |
11.51% |
|
methylprednisolone* |
injection |
powder for injection 1 g (as sodium succinate) |
41.31 |
15.96% |
34.72 |
41.31 |
15.95% |
|
metoclopramide |
oral |
tablet containing metoclopramide hydrochloride 10 mg |
1.21 |
13.30% |
1.05 |
1.21 |
13.22% |
|
metoprolol succinate |
oral |
tablet 190 mg (controlled release) |
73.28 |
13.94% |
63.06 |
73.28 |
13.95% |
|
metoprolol succinate |
oral |
tablet 23.75 mg (controlled release) |
9.93 |
13.94% |
8.55 |
9.93 |
13.90% |
|
metoprolol succinate |
oral |
tablet 47.5 mg (controlled release) |
46.91 |
13.94% |
40.37 |
46.91 |
13.94% |
|
metoprolol succinate |
oral |
tablet 95 mg (controlled release) |
58.62 |
13.94% |
50.45 |
58.62 |
13.94% |
|
mirtazapine |
oral |
tablet 15 mg |
3.18 |
17.75% |
2.62 |
3.18 |
17.61% |
|
mirtazapine |
oral |
tablet 15 mg (orally disintegrating) |
5.49 |
17.75% |
4.52 |
5.49 |
17.67% |
|
mirtazapine |
oral |
tablet 30 mg |
4.78 |
17.75% |
3.93 |
4.78 |
17.78% |
|
mirtazapine |
oral |
tablet 30 mg (orally disintegrating) |
7.32 |
17.75% |
6.02 |
7.32 |
17.76% |
|
mirtazapine |
oral |
tablet 45 mg |
7.96 |
17.75% |
6.55 |
7.96 |
17.71% |
|
mirtazapine |
oral |
tablet 45 mg (orally disintegrating) |
11.03 |
17.75% |
9.07 |
11.03 |
17.77% |
|
mitozantrone |
injection |
injection 20 mg (as hydrochloride) in 10 ml |
61.51 |
14.19% |
52.78 |
61.51 |
14.19% |
|
mitozantrone |
injection |
injection 25 mg (as hydrochloride) in 12.5 ml |
76.85 |
14.19% |
65.94 |
76.85 |
14.20% |
|
mometasone |
application |
cream containing mometasone furoate 1 mg per g, 15 g |
4.52 |
14.93% |
3.85 |
4.52 |
14.82% |
|
mometasone |
application |
lotion containing mometasone furoate 1 mg per g, 30 ml |
7.13 |
14.93% |
6.07 |
7.13 |
14.87% |
|
mometasone |
application |
ointment containing mometasone furoate 1 mg per g, 15 g |
4.52 |
14.93% |
3.85 |
4.52 |
14.82% |
|
nevirapine |
oral |
tablet 200 mg |
198.09 |
20.67% |
157.14 |
198.09 |
20.67% |
|
nevirapine |
oral |
tablet 400 mg (extended release) |
198.09 |
20.67% |
157.14 |
198.09 |
20.67% |
|
olanzapine |
oral |
tablet 10 mg |
33.76 |
43.29% |
19.15 |
25.21 |
24.04% |
|
olanzapine |
oral |
tablet 10 mg (as benzoate) |
33.76 |
43.29% |
19.15 |
25.21 |
24.04% |
|
olanzapine |
oral |
tablet 10 mg (orally disintegrating) |
33.76 |
43.29% |
19.15 |
25.21 |
24.04% |
|
olanzapine |
oral |
tablet 15 mg (orally disintegrating) |
50.63 |
43.29% |
28.71 |
37.81 |
24.07% |
|
olanzapine |
oral |
tablet 2.5 mg |
8.44 |
43.29% |
4.79 |
6.30 |
23.97% |
|
olanzapine |
oral |
tablet 2.5 mg (as benzoate) |
8.44 |
43.29% |
4.79 |
6.30 |
23.97% |
|
olanzapine |
oral |
tablet 20 mg (orally disintegrating) |
67.51 |
43.29% |
38.28 |
50.42 |
24.08% |
|
olanzapine |
oral |
tablet 5 mg |
16.71 |
43.29% |
9.48 |
12.48 |
24.04% |
|
olanzapine |
oral |
tablet 5 mg (as benzoate) |
16.71 |
43.29% |
9.48 |
12.48 |
24.04% |
|
olanzapine |
oral |
tablet 5 mg (orally disintegrating) |
16.71 |
43.29% |
9.48 |
12.48 |
24.04% |
|
olanzapine |
oral |
tablet 7.5 mg |
25.32 |
43.29% |
14.36 |
18.91 |
24.06% |
|
olanzapine |
oral |
tablet 7.5 mg (as benzoate) |
25.32 |
43.29% |
14.36 |
18.91 |
24.06% |
|
olanzapine |
oral |
wafer 10 mg |
33.76 |
43.29% |
19.15 |
25.21 |
24.04% |
|
olanzapine |
oral |
wafer 15 mg |
50.63 |
43.29% |
28.71 |
37.81 |
24.07% |
|
olanzapine |
oral |
wafer 20 mg |
67.51 |
43.29% |
38.28 |
50.42 |
24.08% |
|
olanzapine |
oral |
wafer 5 mg |
16.71 |
43.29% |
9.48 |
12.48 |
24.04% |
|
omeprazole* |
oral |
capsule 20 mg |
5.48 |
13.51% |
4.74 |
5.48 |
13.50% |
|
omeprazole* |
oral |
tablet 20 mg |
5.48 |
13.51% |
4.74 |
5.48 |
13.50% |
|
omeprazole* |
oral |
tablet 20 mg (as magnesium) |
5.48 |
13.51% |
4.74 |
5.48 |
13.50% |
|
pamidronic acid |
injection |
concentrated injection containing disodium pamidronate 15 mg in 5 ml |
17.16 |
19.51% |
13.81 |
15.39 |
10.27% |
|
pamidronic acid |
injection |
concentrated injection containing disodium pamidronate 30 mg in 10 ml |
34.33 |
19.51% |
27.63 |
30.78 |
10.23% |
|
pamidronic acid |
injection |
concentrated injection containing disodium pamidronate 60 mg in 10 ml |
68.65 |
19.51% |
55.26 |
61.54 |
10.20% |
|
pamidronic acid |
injection |
concentrated injection containing disodium pamidronate 90 mg in 10 ml |
102.98 |
19.51% |
82.89 |
92.32 |
10.21% |
|
pantoprazole |
oral |
tablet (enteric coated) 20 mg (as sodium sesquihydrate) |
1.88 |
15.95% |
1.58 |
1.88 |
15.96% |
|
pantoprazole |
oral |
tablet (enteric coated) 40 mg (as sodium sesquihydrate) |
3.87 |
15.95% |
3.25 |
3.87 |
16.02% |
|
perindopril |
oral |
tablet containing perindopril arginine 10 mg |
6.66 |
12.16% |
5.85 |
6.66 |
12.16% |
|
perindopril |
oral |
tablet containing perindopril arginine 2.5 mg |
2.33 |
12.16% |
2.05 |
2.33 |
12.02% |
|
perindopril |
oral |
tablet containing perindopril arginine 5 mg |
4.35 |
12.16% |
3.82 |
4.35 |
12.18% |
|
perindopril |
oral |
tablet containing perindopril erbumine 2 mg |
2.33 |
12.16% |
2.05 |
2.33 |
12.02% |
|
perindopril |
oral |
tablet containing perindopril erbumine 4 mg |
4.35 |
12.16% |
3.82 |
4.35 |
12.18% |
|
perindopril |
oral |
tablet containing perindopril erbumine 8 mg |
6.66 |
12.16% |
5.85 |
6.66 |
12.16% |
|
perindopril with indapamide* |
oral |
tablet containing perindopril arginine 5 mg with indapamide hemihydrate 1.25 mg |
10.55 |
12.90% |
9.19 |
10.55 |
12.89% |
|
perindopril with indapamide* |
oral |
tablet containing perindopril erbumine 4 mg with indapamide hemihydrate 1.25 mg |
10.55 |
12.90% |
9.19 |
10.55 |
12.89% |
|
pioglitazone |
oral |
tablet 15 mg (as hydrochloride) |
14.64 |
18.27% |
11.97 |
14.64 |
18.24% |
|
pioglitazone |
oral |
tablet 30 mg (as hydrochloride) |
22.52 |
18.27% |
18.41 |
22.52 |
18.25% |
|
pioglitazone |
oral |
tablet 45 mg (as hydrochloride) |
29.28 |
18.27% |
23.93 |
29.28 |
18.27% |
|
pravastatin |
oral |
tablet containing pravastatin sodium 10 mg |
2.00 |
13.93% |
1.72 |
2.00 |
14.00% |
|
pravastatin |
oral |
tablet containing pravastatin sodium 20 mg |
3.17 |
13.93% |
2.73 |
3.17 |
13.88% |
|
pravastatin |
oral |
tablet containing pravastatin sodium 40 mg |
4.93 |
13.93% |
4.24 |
4.93 |
14.00% |
|
pravastatin |
oral |
tablet containing pravastatin sodium 80 mg |
7.58 |
13.93% |
6.52 |
7.58 |
13.98% |
|
quetiapine |
oral |
tablet (modified release) 150 mg (as fumarate) |
45.01 |
31.91% |
30.65 |
34.85 |
12.05% |
|
quetiapine |
oral |
tablet (modified release) 200 mg (as fumarate) |
61.33 |
31.91% |
41.76 |
47.49 |
12.07% |
|
quetiapine |
oral |
tablet (modified release) 300 mg (as fumarate) |
89.99 |
31.91% |
61.27 |
69.67 |
12.06% |
|
quetiapine |
oral |
tablet (modified release) 400 mg (as fumarate) |
122.67 |
31.91% |
83.53 |
94.97 |
12.05% |
|
quetiapine |
oral |
tablet (modified release) 50 mg (as fumarate) |
31.81 |
31.91% |
21.66 |
24.63 |
12.06% |
|
quetiapine |
oral |
tablet 100 mg (as fumarate) |
45.01 |
31.91% |
30.65 |
34.85 |
12.05% |
|
quetiapine |
oral |
tablet 200 mg (as fumarate) |
61.33 |
31.91% |
41.76 |
47.49 |
12.07% |
|
quetiapine |
oral |
tablet 25 mg (as fumarate) |
15.91 |
31.91% |
10.83 |
12.31 |
12.02% |
|
quetiapine |
oral |
tablet 300 mg (as fumarate) |
89.99 |
31.91% |
61.27 |
69.67 |
12.06% |
|
rabeprazole |
oral |
tablet containing rabeprazole sodium 10 mg (enteric coated) |
6.74 |
26.71% |
4.94 |
5.88 |
15.99% |
|
rabeprazole |
oral |
tablet containing rabeprazole sodium 20 mg (enteric coated) |
6.74 |
26.71% |
4.94 |
5.88 |
15.99% |
|
raloxifene |
oral |
tablet containing raloxifene hydrochloride 60 mg |
36.54 |
14.06% |
31.40 |
36.54 |
14.07% |
|
ranitidine* |
oral |
tablet 150 mg (as hydrochloride) |
4.33 |
11.07% |
3.85 |
4.33 |
11.09% |
|
ranitidine* |
oral |
tablet 300 mg (as hydrochloride) |
4.33 |
11.07% |
3.85 |
4.33 |
11.09% |
|
riluzole |
oral |
tablet 50 mg |
321.02 |
16.29% |
268.73 |
321.02 |
16.29% |
|
rosuvastatin |
oral |
tablet 10 mg (as calcium) |
16.11 |
37.50% |
10.07 |
12.32 |
18.26% |
|
rosuvastatin |
oral |
tablet 20 mg (as calcium) |
22.93 |
37.50% |
14.33 |
17.54 |
18.30% |
|
rosuvastatin |
oral |
tablet 40 mg (as calcium) |
32.71 |
37.50% |
20.44 |
25.01 |
18.27% |
|
rosuvastatin |
oral |
tablet 5 mg (as calcium) |
10.97 |
37.50% |
6.86 |
8.39 |
18.24% |
|
sertraline |
oral |
tablet 100 mg (as hydrochloride) |
2.26 |
17.91% |
1.86 |
2.26 |
17.70% |
|
sertraline |
oral |
tablet 50 mg (as hydrochloride) |
2.26 |
17.91% |
1.86 |
2.26 |
17.70% |
|
sildenafil |
oral |
tablet 20 mg (as citrate) |
754.68 |
31.79% |
514.77 |
574.01 |
10.32% |
|
telmisartan |
oral |
tablet 40 mg |
5.27 |
36.69% |
3.34 |
3.75 |
10.93% |
|
telmisartan |
oral |
tablet 80 mg |
15.28 |
36.69% |
9.67 |
10.86 |
10.96% |
|
telmisartan with hydrochlorothiazide |
oral |
tablet 40 mg-12.5 mg |
6.68 |
33.33% |
4.45 |
5.25 |
15.24% |
|
telmisartan with hydrochlorothiazide |
oral |
tablet 80 mg-12.5 mg |
16.69 |
33.33% |
11.13 |
13.12 |
15.17% |
|
telmisartan with hydrochlorothiazide |
oral |
tablet 80 mg-25 mg |
18.10 |
33.33% |
12.07 |
14.23 |
15.18% |
|
terbinafine |
oral |
tablet 250 mg (as hydrochloride) |
25.93 |
14.70% |
22.12 |
25.93 |
14.69% |
|
topiramate |
oral |
capsule 15 mg |
9.41 |
20.05% |
7.52 |
9.41 |
20.09% |
|
topiramate |
oral |
capsule 25 mg |
12.72 |
20.05% |
10.17 |
12.72 |
20.05% |
|
topiramate |
oral |
capsule 50 mg |
21.21 |
20.05% |
16.96 |
21.21 |
20.04% |
|
topiramate |
oral |
tablet 100 mg |
33.40 |
20.05% |
26.70 |
33.40 |
20.06% |
|
topiramate |
oral |
tablet 200 mg |
56.12 |
20.05% |
44.87 |
56.12 |
20.05% |
|
topiramate |
oral |
tablet 25 mg |
12.93 |
20.05% |
10.34 |
12.93 |
20.03% |
|
topiramate |
oral |
tablet 50 mg |
21.24 |
20.05% |
16.98 |
21.24 |
20.06% |
|
topotecan |
injection |
powder for i.v. infusion 4 mg (as hydrochloride) |
64.53 |
29.75% |
45.33 |
64.53 |
29.75% |
|
tramadol |
injection |
injection containing tramadol hydrochloride 100 mg in 2 ml |
4.18 |
20.88% |
3.31 |
3.70 |
10.54% |
|
valaciclovir |
oral |
tablet 500 mg (as hydrochloride) |
12.12 |
30.73% |
8.40 |
10.64 |
21.05% |
|
venlafaxine |
oral |
capsule (modified release) 150 mg (as hydrochloride) |
9.75 |
31.89% |
6.64 |
7.80 |
14.87% |
|
venlafaxine |
oral |
capsule (modified release) 37.5 mg (as hydrochloride) |
4.53 |
31.89% |
3.09 |
3.62 |
14.64% |
|
venlafaxine |
oral |
capsule (modified release) 75 mg (as hydrochloride) |
8.00 |
31.89% |
5.45 |
6.39 |
14.71% |
|
zolmitriptan |
oral |
tablet 2.5 mg |
7.85 |
10.30% |
7.04 |
7.85 |
10.32% |
